PT - 期刊文章Au - Lui，Macy Mei-Sze Au - TSE，Hung-Fat Au - Lam，David Chi-Leung Au - Lau，Kui-kai Au - Chan，Carmen Wing-Sze Au - IP，Mary Sau-ManTi - 连续正气道压力可提高阻塞性睡眠呼吸暂停和高血压辅助血压和血清心血管生物标志物 - 10.1183 / 13993003.03687-2020 DP - 2021年1月1日 - 欧洲呼吸期刊PG - 2003687 4099 - //www.qdcxjkg.com/ content/early/2021/03/25/13993003.03687-2020.short 4100 - //www.qdcxjkg.com/content/early/2021/03/25/13993003/25/13993003/25/13993003/25/13993003/25/13993003/25/13993003/25/13993003/25/13993003/25/13993003/25/13993003/25/13993003/25/13993003/25/13993003.full ab - 理由治疗的影响对于阻塞性睡眠呼吸暂停（OSA）减少心血管风险尚不清楚。本研究旨在研究连续正气道压力（CPAP）对OSA和高血压受试者的动态血压（BP）和亚临床心肌损伤的影响。方法具有高血压的受试者，需要至少三种抗高血压药物和中度严重的OSA注册了。符合条件的受试者随机（1：1）接受CPAP治疗或控制（无CPAP）八周。比较了动态BP和血清生物标志物的变化。根据昼夜节律BP模式进行分层分析。结果结果九十个受试者（75％的男性;年龄，51±8年;呼吸暂停 - 低尿剂指数40±8次事件·H-1，平均为3.4抗高血压药物[范围3-6]）被随机化。与对照组相比CPAP处理的组表现出24-H收缩压BP（-4.4mmHg，95％CI -8.7至-0.1，P = 0.046），24-H舒张压BP（-2.9mmHg， 95% CI −5.5 to −0.2, p=0.032), daytime systolic BP (−5.4 mmHg, −9.7 to −1.0, p=0.016) and daytime diastolic BP (−3.4 mmHg, 95% CI −6.1 to −0.8, p=0.012). CPAP treatment was associated with significant BP lowering only in non-dippers, but not in dippers. Serum troponin I (mean difference −1.74 pg·mL−1, 95% CI −2.97 to −0.5, p=0.006) and brain natriuretic peptide (−9.1 pg·mL−1, 95% CI −17.6 to −0.6, p=0.036) were significantly reduced in CPAP compared to control group.Conclusion In a cohort with OSA and multiple cardiovascular risk factors including difficult-to-control hypertension, short-term CPAP treatment improved ambulatory BP and alleviated subclinical myocardial injury and strain.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Lui has nothing to disclose.Conflict of interest: Dr. Tse has nothing to disclose.Conflict of interest: Dr. LAM has nothing to disclose.Conflict of interest: Dr. Lau reports grants, personal fees and non-financial support from Boerhinger Ingelheim, grants and non-financial support from Pfizer, grants from Sanofi, grants from Amgen, non-financial support from Eisai, outside the submitted work.Conflict of interest: Dr. Chan has nothing to disclose.Conflict of interest: M. Ip has nothing to disclose.